Livzon Pharmaceutical Group Inc banner

Livzon Pharmaceutical Group Inc
SZSE:000513

Watchlist Manager
Livzon Pharmaceutical Group Inc Logo
Livzon Pharmaceutical Group Inc
SZSE:000513
Watchlist
Price: 32.65 CNY -0.55% Market Closed
Market Cap: ¥29B

P/S

2.5
Current
11%
Cheaper
vs 3-y average of 2.8

Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.

P/S
2.5
=
Market Cap
¥28.9B
/
Revenue
¥11.7B

Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.

P/S
2.5
=
Market Cap
¥28.9B
/
Revenue
¥11.7B

Valuation Scenarios

Livzon Pharmaceutical Group Inc is trading below its 3-year average

If P/S returns to its 3-Year Average (2.8), the stock would be worth ¥36.56 (12% upside from current price).

Statistics
Positive Scenarios
4/4
Maximum Downside
No Downside Scenarios
Maximum Upside
+60%
Average Upside
24%
Scenario P/S Value Implied Price Upside/Downside
Current Multiple 2.5 ¥32.65
0%
3-Year Average 2.8 ¥36.56
+12%
5-Year Average 2.8 ¥36.64
+12%
Industry Average 3.9 ¥52.13
+60%
Country Average 2.8 ¥36.62
+12%

Forward P/S
Today’s price vs future revenue

Today's Market Cap Revenue Forward P/S
¥28.9B
/
Apr 2026
¥11.7B
=
2.5
Current
¥28.9B
/
Dec 2026
¥12.5B
=
2.3
Forward
¥28.9B
/
Dec 2027
¥13.2B
=
2.2
Forward
¥28.9B
/
Dec 2028
¥14B
=
2.1
Forward

Forward P/S shows whether today’s P/S still looks high or low once future revenue are taken into account.

Peer Comparison

All Multiples
P/S
P/E
All Countries
Close
Market Cap P/S P/E
CN
Livzon Pharmaceutical Group Inc
SZSE:000513
29B CNY 2.5 14.7
US
Eli Lilly and Co
NYSE:LLY
908.9B USD 12.6 36
US
Johnson & Johnson
NYSE:JNJ
547.1B USD 5.7 26
CH
Roche Holding AG
SIX:ROG
248.4B CHF 4.2 20.1
UK
AstraZeneca PLC
LSE:AZN
209.6B GBP 4.7 27.4
CH
Novartis AG
SIX:NOVN
221.1B CHF 5 20.7
US
Merck & Co Inc
NYSE:MRK
277.6B USD 4.2 31.1
IE
Endo International PLC
LSE:0Y5F
244.4B USD 105.4 -83.6
DK
Novo Nordisk A/S
CSE:NOVO B
1.2T DKK 4 12.1
US
Pfizer Inc
NYSE:PFE
149.7B USD 2.4 19.3
US
Bristol-Myers Squibb Co
NYSE:BMY
118.9B USD 407.7 4 516.9
P/E Multiple
Earnings Growth PEG
CN
Livzon Pharmaceutical Group Inc
SZSE:000513
Average P/E: 472.4
14.7
8%
1.8
US
Eli Lilly and Co
NYSE:LLY
36
32%
1.1
US
Johnson & Johnson
NYSE:JNJ
26
8%
3.3
CH
Roche Holding AG
SIX:ROG
20.1
14%
1.4
UK
AstraZeneca PLC
LSE:AZN
27.4
25%
1.1
CH
Novartis AG
SIX:NOVN
20.7
14%
1.5
US
Merck & Co Inc
NYSE:MRK
31.1
14%
2.2
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -83.6 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
12.1
0%
N/A
US
Pfizer Inc
NYSE:PFE
19.3
22%
0.9
US
Bristol-Myers Squibb Co
NYSE:BMY
4 516.9
648%
7

Market Distribution

In line with most companies in China
Percentile
46th
Based on 7 736 companies
46th percentile
2.5
Low
0 — 1.5
Typical Range
1.5 — 5.4
High
5.4 —
Distribution Statistics
China
Min 0
30th Percentile 1.5
Median 2.8
70th Percentile 5.4
Max 5 034 353.9

Livzon Pharmaceutical Group Inc
Glance View

Market Cap
29B CNY
Industry
Pharmaceuticals

Nestled within the bustling pharmaceutical landscape of China, Livzon Pharmaceutical Group Inc. has meticulously carved its path since its inception in 1985, blossoming into a formidable player in the industry. Based in Zhuhai, Guangdong Province, the company has steadily built a diversified portfolio across the pharmaceutical spectrum, focusing on both traditional Chinese medicine and modern biopharmaceutical products. Livzon leverages its robust research and development (R&D) capabilities to produce an extensive range of medications, catering primarily to major therapeutic areas such as cardiovascular, gastrointestinal, anti-infective, and oncology segments. With rigorous standards driving their production lines, they ensure premium quality, which has bolstered their reputation and allowed them to secure numerous patents and proprietary products. Livzon's revenue engine is fueled by its strategic blend of manufacturing prowess and a well-tuned distribution network. The company operates a comprehensive production chain, from raw material sourcing and pharmaceuticals manufacturing to extensive distribution channels stretching across domestic and global markets. It sustains strong collaborations with hospitals, medical institutions, and pharmacies, which facilitate widespread accessibility and market penetration. Additionally, Livzon invests heavily in innovation, aligning with global health demands through strategic partnerships and joint ventures, further pushing the boundaries of research. By balancing traditional medicinal wisdom with cutting-edge technologies, Livzon positions itself as an agile competitor in the ever-evolving pharmaceutical arena, continuously driving value creation and securing its foothold in the global marketplace.

Intrinsic Value
36.26 CNY
Undervaluation 10%
Intrinsic Value
Price ¥32.65
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett